One of the most advanced clinical-stage candidates at RedHill Biopharma Ltd (RDHL) is RHB-105, a new triple combination therapy for the eradication of H. pylori infection in humans. RedHill has successfully completed a Phase 3 clinical trial with RHB-105, reporting positive results in June 2015 from the ERADICATE-Hp study. ERADICATE-Hp was a randomized, double-blind, placebo-controlled…
How Nuvo Research Splitting Into Two Companies Is A Win-Win For Shareholders Last week, Nuvo Research Inc. (NRI.TO) mailed a Management Information Circular to shareholders explaining the impetus and logistics for the planned separation of the company into two separately traded entities, a specialty pharmaceutical business to be called Nuvo Pharmaceuticals Inc., and a drug development…
Earlier in January, I alerted investors to the fact that 22nd Century Group (NYSEMTK: XXII) filed an MRTP application to the U.S. FDA for Brand-A, a code name for the company’s modified risk very low nicotine (VLN) cigarette that contains roughly 95% less nicotine per cigarette versus commercially available brands. MRTP stands for Modified Risk Tobacco Product,…
Last week in San Francisco, I had a good talk with Joseph P. Wagner, PhD, the CEO of BriaCell Therapeutics (BCT.V / BCTXF). He provide a good update on the current situation, which I report to investors in this article. Right now, the company’s is in active preparation to begin the Phase 2 trial, with…
Several months ago I wrote an article highlighting RedHill Biopharma’s (NASDAQ: RDHL) RHB-104, a patent-protected combination of clarithromycin, clofazimine, and rifabutin in a single oral pill, currently in Phase 3 trials for the treatment of Crohn’s disease (CD). I encourage investors to view that article >> HERE << because it provides a very good background on RHB-104…
Shares of Actinium Pharmaceuticals (ATNM) have moved significantly higher over the past month as investors are starting to come to grips with the potential for the company’s two pipeline products, Iomab-B and Actimab-A, both under investigation for the treatment of acute myeloid leukemia (AML). Iomab-B and Actimab-A are specific anti-cancer monoclonal antibodies (mAb) conjugated to alpha…
Last month I wrote a detailed article introducing investors to 22nd Century Group, Inc. (NYSEMKT:XXII), a Clarence, NY-based biopharmaceutical company founded in 1998 with proprietary technology in nicotine biosynthesis and tobacco plant-biotechnology. The company is engaged in the development and commercialization of tobacco harm reduction cigarettes and smoking cessation products, as well as the contract…
Yes, investors, there are still millions of people who smoke cigarettes! Bafflingly, despite all the science and meta-analyses, U.S. Surgeon General warnings and CDC case studies, the World Health Organization (WHO) estimates 5.6 trillion cigarettes were sold globally in 2014. Forty percent of these sales took place in Asia, where roughly two-thirds of the population…
Actinium Pharmaceuticals (NYSEMKT: ATNM) had a very successful showing at the American Society of Hematology (ASH) annual meeting held over the past few days in Orlando, FL. The highlight of the event for the company was a poster presentation of Phase 1 clinical data with Actimab-A, the company’s CD33 targeting alpha particle immunotherapy for the…
Acute Leukemia – A Quick Overview Leukemias are cancers of the blood and involve bone marrow, circulating white blood cells, and organs such as the spleen and lymph nodes. The cancer usually manifests in the bone marrow and results in a high number of abnormal white blood cells called blasts (also called leukemia cells). The…